Dr. Marshall earned his MD at Johns Hopkins University and completed his Psychiatry residence at Columbia University, where he attained Associate Professor before leaving to pursue therapeutics research in biotechnology. At Columbia, he was PI, Co-PI, or Advisor to ~30 research grants funded through NIH, nonprofits and industry, and he has published more than 140 peer-reviewed publications, book chapters or books, with a primary focus on the diagnosis and treatment of trauma-related disorders including PTSD, complicated grief, and psychiatric problems and disorders related to the 9/11 attack in New York city. He has also published on the treatment of multiple anxiety disorders including social anxiety disorder, obsessive-compulsive disorder, panic disorder. After leaving academia to work in biotechnology, Dr. Marshall has developed and led programs across multiple CNS disorders, in both neurology and psychiatry, in rare disease, and in hepatology and pediatric oncology. Dr. Marshall co-founded ProTara Therapeutics as Chief Medical Officer, a clinical-stage rare disease company recently listed on NASDAQ. Prior to that, he held medical leadership roles of increasing responsibility at Sepracor, Sunovion, Euthymics, Neurovance, and Retrophin.